Oncobox
Oncobox is a YC Summer 2017 (S17) company. Based in Walnut, CA, USA. Team of 11.
About Oncobox
Summary
Oncobox builds a molecular profiling diagnostic for oncologists treating late-stage cancer patients. Its platform, Oncobox Dx, analyzes tumor DNA, RNA, and molecular pathways to rank the effectiveness of over 170 targeted and immunotherapy drugs for each individual patient. It replaces the current trial-and-error approach to drug selection, where oncologists have no data-driven basis for choosing among a large and costly set of options.
Business model
Fee for diagnostic testing, accessed through affiliated clinics that send tumor samples to Oncobox's laboratory.
Go-to-market
Oncologists and hospital clinicians are the primary users, with patients accessing testing through affiliated clinics; the company also pursues partnerships with pharma, payers, and genomic centers.
From the Y Combinator listing
Finding the right cancer drug for each patient.
Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would most effectively fight individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe and Asia on 900 patients with various late-stage cancers, Oncobox increased the effectiveness of targeted therapies from 25% to 64%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock. They don’t always know which medication will be most effective for their patients. Because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Dx analyses tumor DNA, RNA, and molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We actively seek partners from pharma, hospitals/clinicians, payers, and genomic centers. Feel free to contact us at hello@oncobox.com. Our team and the scientific advisory board consisting of leading scientists and researchers from UCLA, Stanford, Johns Hopkins University, Boston University, Tufts University, and Rutgers University.
Facts
- Healthcare / Healthcare -> Diagnostics
- Walnut, CA, USA
- 11
- Active
- Early
Founders (2)
- Andrew Garazha
- Anton Buzdin
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works